Real-world dapagliflozin experience in patients with heart failure in United Kingdom.

Trial Identifier: D169CR00001
Sponsor: AstraZeneca
NCTID:: NCT05188144
Start Date: November 2021
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Congestive Heart Failure

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United Kingdom, Berkshire Reading, Berkshire, United Kingdom, RG1 5AN
United Kingdom, Cornwall Truro, Cornwall, United Kingdom, TR1 3LJ
United Kingdom, County Armagh Portadown, County Armagh, United Kingdom, BT63 5QQ
United Kingdom, Devon Barnstaple, Devon, United Kingdom, EX31 4JB
United Kingdom, Essex Westcliff on Sea, Essex, United Kingdom, SS0 0RY
United Kingdom, Glamorgan Port Talbot, Glamorgan, United Kingdom, SA12 7BR
United Kingdom, Greater London London, Greater London, United Kingdom, SE5 9RS
United Kingdom, Staffordshire Stoke-on-Trent, Staffordshire, United Kingdom, AT4 6QG
United Kingdom, Sussex Brighton, Sussex, United Kingdom, BN2 5BE
United Kingdom, Warwickshire Coventry, Warwickshire, United Kingdom, CV2 2DX